MIRM

96.1800.70%
LF

Laurent Fischer

Independent Director

Dr. Laurent Fischer, M.D., is Independent Chair of Shinobi Therapeutics, Inc. from November 2025. He served as Chair of the Board of Teal Omics Inc. until 2025. He had been the Independent Supervisory Director of AtaiBeckley Inc. (formerly known as Atai Beckley N.V.) (formerly known as Atai Life Sciences N.V.) since May 2024 and served as its Director until September 11, 2026. He is Advisor of FORM Life Ventures. He served as a Senior Advisor of Frazier Management, L.L.C. since March 2017 till May 2022. He joined the firm in March 2017. He was on the Frazier Life Sciences team and has several years of drug development and commercialization experience in the biopharmaceutical industry. He served as Chief Executive Officer and Director at Adverum Biotechnologies, Inc. since June 15, 2020 until December 9, 2025 and was its President since June 2021 until December 9, 2025 and served as Interim Chief Medical Officer since October 22, 2021 until 2022. He serves as Independent Director at Lycia Therapeutics, Inc. from December 2019. He had been the Chief Executive Officer of Tobira Therapeutics, Inc. since March 26, 2014, until November 2016. He is Managing Publisher of Nordbayerischer Kurier newspaper. Dr. Fischer served as the Chief Executive Officer and President at SillaJen Biotherapeutics, Inc. since June 28, 2012. He served as Chief Executive Officer and President of Jennerex Biotherapeutics, Inc., from 2012 to March 2014. He served as Co-Chair of the Liver Forum. He serves as Senior Vice President and Head of the Liver Therapeutic Area at Allergan from November 2016 to June 2020. He served as an Acting Chief Executive Officer of Tobira Therapeutics, Inc. until March 26, 2014. He is involved in and managed four healthcare companies. He has several years of drug development and commercial experience in the biopharmaceutical industry. Dr. Fischer co-founded Ocera Therapeutics, Inc. in 2004. He served as the President and Chief Executive Officer of Ocera Therapeutics, Inc. since 2005, where he led the approval of Zysa(R), the first treatment ever approved for Irritable Bowel Syndrome in Europe and developed the first ammonia scavenger for the treatment of complications of liver disease. Dr. Fischer served as President and Chief Executive Officer of Auxeris Therapeutics, Inc. from 2003 to 2005. He served as Vice President of Corporate Development and Chief Medical Officer of MedVantx, Inc. He served as President and Chief Operating Officer of Rxcentric, Inc., from 1999 to 2000. From 1997 to 1999, Dr. Fischer also served as Senior Vice President of the Global Virology Franchise at DuPont-Merck, Inc., 1997 to 1999 and Dupont Pharmaceuticals, where he launched the breakthrough anti-HIV drug, Sustiva. From 1993 to 1997, Dr. Fischer served as Medical Director for Hoffmann-LaRoche Ltd.'s from 1995 to 1997 where he was involved in the launch of INVIRASE(R) and developed FORTOVASE, protease inhibitors for the treatment of HIV. He has held senior management positions at DuPont-Merck and DuPont Pharmaceuticals. Dr. Fischer served as the Executive Chairman of Tobira Therapeutics, Inc. He has been an Independent Director of Mirum Pharmaceuticals, Inc., (NASDAQ: MIRM) since June 2019. He served as Chief Medical Officer and Vice President of Corporate Development of medication management company MedVantx Inc. from 2001 to 2003. Dr. Fischer was Chairman of the Board of CTI BioPharma Corp. from September 26, 2017 to June 26, 2023 and as its Director from July 21, 2017 to June 26, 2023. He serves as Chairman of the Board of Directors of the AIDS Healthcare Foundation. He served as Chairman at Jennerex, Inc., from 2012 to March 2014. He serves as Deputy Chairman of Supervisory Board of dpa Deutsche Presse-Agentur GmbH. He served as Vice Chairman at Ocera Therapeutics, Inc. He has been a Director of Panacos Pharmaceuticals Inc. since October 2006. He serves as Director of Poesis Therapeutics Ltd. He has been a Member of Board of Directors of the AIDS Healthcare Foundation since 2001. He served as a Director of Tobira Therapeutics, Inc. from June 2009 to October 2016. He served as a Director of Ocera Therapeutics, Inc. He previously served as Director of Senti Biosciences and Senior Advisor of Frazier Healthcare Partners. He served as Director of SillaJen Biotherapeutics, Inc., since June 28, 2012. Dr. Fischer received his Medical Degree from the University of Geneva and his Doctorate in Medicine from the Geneva Medical School, Switzerland.

Positions